Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
V000x
- Development stage
- Preclinical
- Lead developer
- NewLimit
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
V000x is an investigational mRNA-based epigenetic reprogramming therapeutic being developed by NewLimit for the treatment of chronic kidney disease (CKD) and cardiometabolic diseases. The program utilizes transient mRNA delivered via specialized lipid nanoparticles (LNPs) designed to bypass default liver uptake and target endothelial cells in the kidney. By delivering a proprietary combination of transcription factors, V000x aims to restore youthful function to aged or diseased endothelial cells, thereby reversing the course of kidney disease and preserving renal function.
- Other names
- NewLimit kidney programNewLimit vascular program
Beyond the preview
Go deeper on V000x.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on V000x.